These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8757970)

  • 1. Acquired sideroblastic anaemia induced by a copper-chelating agent.
    Perry AR; Pagliuca A; Fitzsimons EJ; Mufti GJ; Williams R
    Int J Hematol; 1996 Jul; 64(1):69-72. PubMed ID: 8757970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired sideroblastic anaemia during treatment of Wilson's disease with triethylene tetramine dihydrochloride.
    Condamine L; Hermine O; Alvin P; Levine M; Rey C; Courtecuisse V
    Br J Haematol; 1993 Jan; 83(1):166-8. PubMed ID: 8435326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wilson's disease treatment by triethylene tetramine dihydrochloride (trientine, 2HCl): long-term observations.
    Morita J; Yoshino M; Watari H; Yoshida I; Motohiro T; Yamashita F; Okano Y; Hashimoto T
    Dev Pharmacol Ther; 1992; 19(1):6-9. PubMed ID: 1307347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trientine-induced neurological deterioration in a patient with Wilson's disease.
    Kim B; Chung SJ; Shin HW
    J Clin Neurosci; 2013 Apr; 20(4):606-8. PubMed ID: 23274038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excess copper chelating therapy for Wilson disease induces anemia and liver dysfunction.
    Harada M; Miyagawa K; Honma Y; Hiura M; Shibata M; Matsuhashi T; Abe S; Harada R; Tabaru A
    Intern Med; 2011; 50(14):1461-4. PubMed ID: 21757830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wilson's disease.
    Walshe JM
    Lancet; 2007 Mar; 369(9565):902. PubMed ID: 17368141
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of Wilson's disease with triethylene tetramine hydrochloride (Trientine).
    Dubois RS; Rodgerson DO; Hambidge KM
    J Pediatr Gastroenterol Nutr; 1990 Jan; 10(1):77-81. PubMed ID: 2324883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oral chelators in treatment of patients with Wilson disease.
    Weiss KH; Thurik F; Gotthardt DN; Schäfer M; Teufel U; Wiegand F; Merle U; Ferenci-Foerster D; Maieron A; Stauber R; Zoller H; Schmidt HH; Reuner U; Hefter H; Trocello JM; Houwen RH; Ferenci P; Stremmel W;
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1028-35.e1-2. PubMed ID: 23542331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triethylene-tetramine (trien) therapy for Wilson's disease.
    Saito H; Watanabe K; Sahara M; Mochizuki R; Edo K; Ohyama Y
    Tohoku J Exp Med; 1991 May; 164(1):29-35. PubMed ID: 1926144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trientine induced colitis during therapy for Wilson disease: a case report and review of the literature.
    Boga S; Jain D; Schilsky ML
    BMC Pharmacol Toxicol; 2015 Nov; 16():30. PubMed ID: 26589720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wilson's disease.
    Ala A; Walker AP; Ashkan K; Dooley JS; Schilsky ML
    Lancet; 2007 Feb; 369(9559):397-408. PubMed ID: 17276780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment of Wilson's disease with triethylene tetramine dihydrochloride (trientine).
    Dahlman T; Hartvig P; Löfholm M; Nordlinder H; Lööf L; Westermark K
    QJM; 1995 Sep; 88(9):609-16. PubMed ID: 7583074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Wilson's disease with trientine (triethylene tetramine) dihydrochloride.
    Walshe JM
    Lancet; 1982 Mar; 1(8273):643-7. PubMed ID: 6121964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of cardiovascular autonomic dysfunction following anti-copper therapy in Wilson's disease.
    Deguchi K; Sasaki I; Touge T; Tsukaguchi M; Ikeda K; Shimamura M; Urai Y; Watanabe S; Takeuchi H; Kuriyama S
    J Neurol; 2005 Apr; 252(4):495-7. PubMed ID: 15726258
    [No Abstract]   [Full Text] [Related]  

  • 15. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
    Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
    J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical recommendations and new therapies for Wilson's disease.
    Brewer GJ
    Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease.
    Siegemund R; Lössner J; Günther K; Kühn HJ; Bachmann H
    Acta Neurol Scand; 1991 Jun; 83(6):364-6. PubMed ID: 1887758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Copper chelation in patients with Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride.
    Walshe JM
    Q J Med; 1973 Jul; 42(167):441-52. PubMed ID: 4728043
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Wilson's disease with triethylene tetramine dihydrochloride. A case report.
    Haslam RH; Sass-Kortsak A; Stout W; Berg M
    Dev Pharmacol Ther; 1980; 1(5):318-24. PubMed ID: 7438976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of administered triethylene tetramine dihydrochloride in humans.
    Kodama H; Murata Y; Iitsuka T; Abe T
    Life Sci; 1997; 61(9):899-907. PubMed ID: 9284083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.